Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Artele Biosciences, Inc. on December 20, 2024. The company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market under the symbol ARTL.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (December 4, 2024), 3,227,700 shares were outstanding. A total of 1,319,986 shares (40.9%) were represented at the meeting, constituting a quorum. The following matters were approved:
- Election of Directors: Two Class I nominees were re-elected to serve until the 2027 annual meeting:
- Steven Kelly: 442,956 For, 64,966 Against, 11,497 Abstain.
- R. Martin Emanuele, Ph.D.: 461,960 For, 45,962 Against, 11,497 Abstain.
- Ratification of Auditors: The appointment of Malone Bailey LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified.
- Votes: 1,258,378 For, 57,083 Against, 4,525 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the re-election of Steven Kelly and R. Martin Emanuele, Ph.D. as directors.
- Confirm the ratification of Malone Bailey LLP as the independent auditor for fiscal year 2024.
- Note the significant number of broker non-votes (800,567) regarding the director elections.
- Review the company's upcoming 10-K filing for the fiscal year ending December 31, 2024, for financial performance data not included in this 8-K.